Option Care Health (NASDAQ:OPCH) Upgraded at Zacks Investment Research

Option Care Health (NASDAQ:OPCHGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Zacks.com reports. The firm currently has a $32.00 price objective on the stock. Zacks Investment Research‘s target price points to a potential upside of 7.71% from the stock’s current price.

According to Zacks, “Option Care Health Inc provides infusion and home care management solutions. The Company offers products, services and condition-specific clinical management programs for gastrointestinal abnormalities, infectious diseases, cancer, organ and blood cell transplants, bleeding disorders and heart failures. Option Care Health Inc., formerly known as BioScrip Inc., is based in Denver, United States. “

Shares of NASDAQ:OPCH opened at $29.71 on Thursday. Option Care Health has a 12-month low of $16.02 and a 12-month high of $29.78. The stock has a market cap of $5.36 billion, a PE ratio of 38.58, a P/E/G ratio of 1.39 and a beta of 1.38. The business has a 50 day moving average of $26.16 and a 200-day moving average of $25.79. The company has a quick ratio of 1.15, a current ratio of 1.55 and a debt-to-equity ratio of 0.90.

Option Care Health (NASDAQ:OPCHGet Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.17. Option Care Health had a return on equity of 10.07% and a net margin of 4.07%. The company had revenue of $927.19 million during the quarter, compared to analysts’ expectations of $917.68 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business’s revenue was up 15.2% on a year-over-year basis. Equities research analysts expect that Option Care Health will post 0.93 earnings per share for the current year.

In other news, COO Harriet Booker sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, March 7th. The stock was sold at an average price of $26.12, for a total transaction of $156,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 18,000 shares of company stock valued at $461,460. Corporate insiders own 47.00% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. acquired a new stake in shares of Option Care Health in the first quarter valued at approximately $230,000. Norges Bank acquired a new stake in shares of Option Care Health in the fourth quarter valued at approximately $42,794,000. BlackRock Inc. raised its position in shares of Option Care Health by 4.6% in the fourth quarter. BlackRock Inc. now owns 16,586,493 shares of the company’s stock valued at $471,721,000 after buying an additional 726,527 shares in the last quarter. Woodline Partners LP raised its position in shares of Option Care Health by 243.7% in the fourth quarter. Woodline Partners LP now owns 232,958 shares of the company’s stock valued at $6,625,000 after buying an additional 165,188 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Option Care Health by 4.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 232,896 shares of the company’s stock valued at $6,623,000 after buying an additional 9,099 shares in the last quarter. Institutional investors own 97.80% of the company’s stock.

Option Care Health Company Profile (Get Rating)

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

See Also

Get a free copy of the Zacks research report on Option Care Health (OPCH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.